Therapeutic Potential of Mipomersen in the Management of Familial Hypercholesterolaemia

Author： Gelsinger Carmen   Steinhagen-Thiessen Elisabeth   Kassner Ursula  

Publisher： Adis International

ISSN： 0012-6667

Source： Drugs, Vol.72, Iss.11, 2012-07, pp. : 1445-1455

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pravastatin for children with familial hypercholesterolaemia

By  

Inpharma, Vol. 1, Iss. 1448, 2004-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

PGD and familial hypercholesterolaemia

By  

Reproductive BioMedicine Online, Vol. 16, Iss. 2, 2008-02 ,pp. : 307-307

Reproductive Healthcare Ltd

Access to resources Recommend Favorite

The potential of mipomersen, an ApoB synthesis inhibitor, to reduce necessity for LDL-apheresis in patients with heterozygous familial hypercholesterolemia and coronary artery disease

By Vogt Anja   Parhofer Klaus G  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 6, 2013-04 ,pp. : 691-697

Informa Healthcare

Access to resources Recommend Favorite

Mipomersen as a potential adjunctive therapy for hypercholesterolemia

By Patel Neeraj   Hegele Robert A  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 15, 2010-10 ,pp. : 2569-2572

Informa Healthcare

Access to resources Recommend Favorite

Cerivastatin: A Review of its Pharmacological Properties and Therapeutic Efficacy in the Management of Hypercholesterolaemia

By Plosker G.L.   Dunn C.J.   Figgitt D.P.  

Drugs, Vol. 60, Iss. 5, 2000-11 ,pp. : 1179-1206

Adis International

Access to resources Recommend Favorite